<DOC>
	<DOCNO>NCT03068624</DOCNO>
	<brief_summary>This clinical research study divide 2 part : leukapheresis treatment . In leukapheresis part , white blood cell call T cell collect participant make specialized CD8+T cell . To make specialized CD8+T cell , researcher separate T cell blood treat able target melanoma cell . The blood cell give back participant treatment part study . This know `` adoptive T cell transfer '' `` adoptive T cell therapy '' . This consent form treatment part study . The goal clinical research study learn safety give CD8+T cell ipilimumab , cyclophosphamide , IL-2 ( aldesleukin ) participant uveal melanoma metastatic ( spread ) . Researchers also want learn combination help control disease .</brief_summary>
	<brief_title>Study Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells Anti-CTLA4 Patients With Metastatic Uveal Melanoma</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , participant assign dose level CD 8+ T cell base participant join study . Up 3 dose level CD 8+T cell test . At least 3 participant enrol dose level . After first group receive dose level CD 8+ T cell , another group enrol high low dose level base side effect see . It possible third group enrol high low dose level second group . All participant receive dose level drug study . Study Drug Administration : Participant receive cyclophosphamide vein 30-60 minute Day -2 ( 2 day participant receives CD8+ T cell ) . If doctor think need , participant give standard drug help decrease risk side effect . Participant may ask study staff information drug give risk . On Day -1 participant admit hospital hepatic arterial catheter place . This catheter sterile flexible tube place blood vessel participant 's liver participant local anesthesia . Participant 's doctor explain procedure participant detail , participant require sign separate consent form . Participant stay hospital overnight placement . On Day 0 , participant receive CD8+ T cell catheter 60 minute . Participant stay hospital overnight dose . Starting within 6 hour CD8+T cell infusion 2 time day 14 day , participant receive aldesleukin injection skin around participant 's abdomen . Participant teach give participant injection . On Days 1 , 22 , 43 , 64 , participant receive ipilimumab vein 90 minute . Study Visits : On Day -2 : - Participant physical exam . - Blood ( 1 tablespoon ) drawn routine test . This routine blood draw include pregnancy test participant become pregnant . To continue participation study , participant pregnant . On Days 0 , 7 , 14 , 22 , 28 , 35 , 43 , 49 , 56 , 64 , 70 , 77 , 84 , 112 , 140 : - Participant physical exam . - Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive participant 's body . - Sometime Days 35 42 Days 77 84 , participant CT scan check status disease . On Day 3 , blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive participant 's body . If doctor think need check status disease , blood ( 1½ tablespoon ) draw every 3-6 month 3 year . The study test may repeat participant may additional test perform anytime doctor think need . Some study test may do participant 's local clinic participant return MD Anderson . The study staff discus participant . Length Treatment : The treatment portion study last Day 64 . Participant longer able take study drug disease get bad , intolerable side effect occur , participant unable follow study direction . Participation study follow-up . End-of-Study Visit : At Day 168 : - Participant physical exam . - Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive participant 's body . Follow-Up : Every 3 month Day 84 , unless disease get bad participant start another cancer therapy , participant CT scan x-ray check status disease . Every 3 month 5 year , study staff call participant ask participant 's doctor participant . If participant call , call last 10-15 minute . If doctor think need , participant return clinic every 4-6 week often doctor think need . Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive participant 's body . This investigational study . Specialized CD8+T cell FDA approve commercially available . They currently use research purpose . Cyclophosphamide , ipilimumab , aldesleukin FDA approve commercially available treatment uveal melanoma . Up 30 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Eligibility Pheresis : ( Turnstile 1 ) Histopathologic documentation melanoma concurrent diagnosis metastatic disease . A diagnosis uveal melanoma make clinically without primary tissue evaluation , base history record . A prior history brachytherapy eye sufficient clinical support diagnosis uveal melanoma . 2 . Male female subject &gt; /= 18 year age . 3 . Expression HLAA:0201 . 4 . ECOG/ Zubrod performance status 01 . 5 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study manner risk pregnancy minimize . Suggested precaution use minimize risk pregnancy least 1 month start therapy , woman study 3 month completion study . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal . 6 . Male patient must willing able use acceptable method birth control , least 3 month completion study , sexual partner WOCBP . 7 . Willing able give inform consent . 8 . Toxicity related prior therapy must either return &lt; /= grade 1 , baseline , deem irreversible . Certain nonserious exception include alopecia , hypothyroidism , neuropathy , nausea , adrenocortical deficiency require physiologic replacement dose steroid , condition note approved PI . 9 . Eligibility T cell infusion ( Includes Cyclophosphamide , T cell , antiCTLA4 infusion s.c. IL2 ) ( Turnstile 2 ) ( Note : evaluate least 1 week T cell infusion ) . ECOG/Zubrod performance status 01 . 10 . Bidimensionally measurable disease palpation clinical exam , radiographic image per irRC . 11 . At least 4 week must elapse since last chemotherapy , target therapy , immunotherapy , radiotherapy , liverdirected therapy , major surgery . At least 6 week nitrosoureas , mitomycin C liposomal doxorubicin . If start Tcell administration , ipilimumab infusion must least 21 day apart . 12 . Toxicity related prior therapy must either return &lt; /=grade 1 , baseline , deem irreversible . Certain nonserious exception include alopecia , hypothyroidism , neuropathy , nausea , adrenocortical deficiency require physiologic replacement dose steroid , condition note approved PI . 13 . Persons reproductive potential must agree use utilize adequate method contraception throughout treatment least 3 month completion study . 14 . Willing able give inform consent . 15 . Patients must liver metastasis . 1 . Exclusion Criteria Leukapheresis : Any malignancy patient diseasefree less 2 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix breast , melanoma insitu . 2 . Pregnant woman , nurse mother , men woman reproductive ability unwilling use effective contraception . Women childbearing potential positive pregnancy test within 3 day prior pheresis . 3 . Clinically significant pulmonary dysfunction , determine medical history physical exam . Patients identify undergo pulmonary function test FEV1 &lt; 2.0 L DLCO ( corr Hgb ) &lt; 50 % exclude . 4 . Significant cardiovascular abnormality define one following : • Congestive heart failure , • Clinically significant hypotension , • Symptoms coronary artery disease ( angina , dyspnea ) , • Presence cardiac arrhythmia EKG require drug therapy , 5 . Autoimmune disease : Patients history Inflammatory Bowel Disease exclude study , patient history autoimmune disease ( e.g . Systemic Lupus Erythematosus , vasculitis , infiltrate lung disease ) whose possible progression treatment would consider Investigator unacceptable . Acceptable exclusion include : Hashimoto 's thyroiditis , Type 1 diabetes mellitus , localize inactive condition approval PI . 6 . Any underlying medical psychiatric condition , opinion Investigator , make administration study drug hazardous obscure interpretation adverse event , condition associate frequent diarrhea . 7 . Positive screening test HIV , Hep B , Hep C. If positive result indicative true active chronic infection , patient treat . 8 . Exclusion Criteria Treatment : CBC Chemistry profile prior cyclophosphamide T cell infusion : • WBC &lt; /= 2000/uL • Hct &lt; /= 24 % Hb &lt; /=8 g/dL • ANC &lt; /= 1000 • Platelets &lt; /= 50,000 • Creatinine &gt; /= 3.0 x ULN • AST/ALT &lt; /= 5 x ULN ( since patient liver metastasis ) • Bilirubin &gt; /=3 x ULN 9 . Pregnant woman , nurse mother , men woman reproductive ability unwilling use effective contraception . Women childbearing potential positive pregnancy test within 3 day prior entry . 10 . Steroids ( prednisone equivalent dos &gt; 10 mg ) permit 3 day prior T cell infusion concurrently therapy . Exceptions include use systemic prednisone equivalent dos &lt; /= 10 mg/ day , topical steroid physiologic replacement dose steroid adrenocortical deficiency . 11 . Any nononcology vaccine therapy use prevention infectious disease within 1 month ipilimumab dose . 12 . Patients may treatment cancer aside include protocol . Patients may undergo another form treatment concurrently study . Oncology supportive treatment growth factor , bone modifying agent , pain nausea management allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Melanoma Other Malignant Neoplasms Skin</keyword>
	<keyword>Metastatic uveal melanoma</keyword>
	<keyword>Autologous CD8+ T cell</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>Proleukin</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Yervoy</keyword>
	<keyword>BMS-734016</keyword>
	<keyword>MDX010</keyword>
</DOC>